Additionally, beyond repressing AR and ERα activity, SAFB2 has been shown to suppress breast cancer progression by inhibiting the Wnt/β-catenin pathway via NFAT5 (Zhen et al., 2023). Here, ESR1 is linked to breast carcinoma.